Effects of Long-term Thrombin Inhibition (Dabigatran Etexilate) on Spontaneous Thrombolytic Activity During the Progression of Atherosclerosis in ApoE-LDLR Double-Knockout Mice

Overview

Journal Korean Circ J

Date 2020 Jul 30

PMID 32725990

Citations 4

Authors

Tomohide Sanda

Manami Yoshimura

Kanae Hyodo

Hiromitu Ishii

Tsutomu Yamashita

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Atherosclerosis is characterized by a hypercoagulable state, during which coagulation and fibrinolytic factors are activated simultaneously. However, details regarding the thrombolytic pathway in this context remain unknown. Here we investigated how direct long-term inhibition of thrombin influenced spontaneous thrombolytic activity during atherosclerotic progression in apolipoprotein E (ApoE)⁻/⁻-low density lipoprotein receptor (LDLR)⁻/⁻ double-knockout mice.

Methods: All mice received either standard chow (placebo group) or dabigatran-containing chow for 22 weeks, after which we evaluated them. The amount of atherosclerosis was estimated as the ratio of the atherosclerotic area to the total aortic intimal area. In addition, we used immunohistochemistry to analyze the expression of tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), thrombin activatable fibrinolysis inhibitor (TAFI), and endothelial nitric oxide synthase (eNOS) in atherosclerotic regions. To evaluate thrombolysis, we used a He-Ne laser to induce thrombosis in vessels of the cremaster muscle and then measured the thrombus volume over time.

Results: The atherosclerotic area was smaller and thrombolytic activity greater in the dabigatran-treated group than in the placebo group. Furthermore, according to the thrombolysis model, spontaneous thrombolytic activity was increased in the dabigatran-treated mice compared with the placebo mice. In support of these results, immunohistochemistry demonstrated decreased expression of PAI-1 and TAFI but increased expression of eNOS in the dabigatran group compared with the placebo group. However, t-PA expression did not differ between groups.

Conclusions: Direct long-term inhibition by dabigatran etexilate of thrombin led to an increase in spontaneous thrombolytic activity decreasing the expression of PAI-1 and TAFI.

Citing Articles

Comparative Cardioprotective Effectiveness: NOACs vs. Nattokinase-Bridging Basic Research to Clinical Findings.

Muric M, Nikolic M, Todorovic A, Jakovljevic V, Vucicevic K Biomolecules. 2024; 14(8).

PMID: 39199344 PMC: 11352257. DOI: 10.3390/biom14080956.

Direct Oral Anticoagulants for Stroke and Systemic Embolism Prevention in Patients with Left Ventricular Thrombus.

Badescu M, Sorodoc V, Lionte C, Ouatu A, Haliga R, Costache A J Pers Med. 2023; 13(1).

PMID: 36675819 PMC: 9866081. DOI: 10.3390/jpm13010158.

Application of fucoidan as treatment for cardiovascular and cerebrovascular diseases.

Wang K, Xu X, Wei Q, Yang Q, Zhao J, Wang Y Ther Adv Chronic Dis. 2022; 13:20406223221076891.

PMID: 35432845 PMC: 9008857. DOI: 10.1177/20406223221076891.

Another Unmet Need against Residual Risk of Atherosclerotic Cardiovascular Disease: Can "Thrombin Pathway" Be a New Target for Therapy?.

Kim H, Tantry U, Gurbel P, Jeong Y Korean Circ J. 2020; 50(9):817-821.

PMID: 32812410 PMC: 7440994. DOI: 10.4070/kcj.2020.0287.

References

Bouchard L, Vohl M, Lebel S, Hould F, Marceau P, Bergeron J . Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity. Obes Surg. 2010; 20(4):492-9. DOI: 10.1007/s11695-010-0079-1. View

Zhu Y, Carmeliet P, Fay W . Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation. 1999; 99(23):3050-5. DOI: 10.1161/01.cir.99.23.3050. View

Stangier J, Clemens A . Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009; 15 Suppl 1:9S-16S. DOI: 10.1177/1076029609343004. View

Adams Jr H, Brott T, Furlan A, Gomez C, Grotta J, Helgason C . Guidelines for Thrombolytic Therapy for Acute Stroke: a Supplement to the Guidelines for the Management of Patients with Acute Ischemic Stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American.... Stroke. 1996; 27(9):1711-8. View

Esmon C . Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost. 2013; 111(4):625-33. DOI: 10.1160/TH13-09-0730. View

Ross J, Stagliano N, Donovan M, Breitbart R, Ginsburg G . Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann N Y Acad Sci. 2002; 947:271-92; discussion 292-3. View

Kakar P, Watson T, Lip G . Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X. Curr Opin Investig Drugs. 2007; 8(3):256-65. View

Ozmen S, Ayhan S, Demir Y, Siemionow M, Atabay K . Impact of gradual blood flow increase on ischaemia-reperfusion injury in the rat cremaster microcirculation model. J Plast Reconstr Aesthet Surg. 2007; 61(8):939-48. DOI: 10.1016/j.bjps.2007.05.017. View

Kang K, Choi S, Cho M, Lee C, Kim S . Thrombin induces nitric-oxide synthase via Galpha12/13-coupled protein kinase C-dependent I-kappaBalpha phosphorylation and JNK-mediated I-kappaBalpha degradation. J Biol Chem. 2003; 278(19):17368-78. DOI: 10.1074/jbc.M300471200. View

10.

Lippi G, Franchini M, Targher G . Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol. 2011; 8(9):502-12. DOI: 10.1038/nrcardio.2011.91. View

11.

Fusaro M, Dalle Carbonare L, Dusso A, Arcidiacono M, Valenti M, Aghi A . Differential Effects of Dabigatran and Warfarin on Bone Volume and Structure in Rats with Normal Renal Function. PLoS One. 2015; 10(8):e0133847. PMC: 4524674. DOI: 10.1371/journal.pone.0133847. View

12.

Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. DOI: 10.1056/NEJMoa0905561. View

13.

Wang T, Gona P, Larson M, Tofler G, Levy D, Newton-Cheh C . Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006; 355(25):2631-9. DOI: 10.1056/NEJMoa055373. View

14.

Davies M . Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation. 1996; 94(8):2013-20. DOI: 10.1161/01.cir.94.8.2013. View

15.

Moncada S, Higgs E . Nitric oxide and the vascular endothelium. Handb Exp Pharmacol. 2006; (176 Pt 1):213-54. DOI: 10.1007/3-540-32967-6_7. View

16.

Du H, Yin M, Ye H, Shang Y, Dai X, Jing W . [Expression profiles of lipid metabolism-related genes in liver of apoE(-/-)/LDLR(-/-) mice]. Zhonghua Bing Li Xue Za Zhi. 2008; 36(11):751-5. View

17.

Stangier J, Rathgen K, Stahle H, Gansser D, Roth W . The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64(3):292-303. PMC: 2000643. DOI: 10.1111/j.1365-2125.2007.02899.x. View

18.

Vercauteren E, Peeters M, Hoylaerts M, Lijnen H, Meijers J, Declerck P . The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency. J Thromb Haemost. 2012; 10(12):2555-62. DOI: 10.1111/jth.12036. View

19.

Oda E, Sano T, Yamashita T, Ijiru Y, Giddings J, Yamamoto J . Varying the ratio of dietary n-6/n-3 polyunsaturated fatty acid alters the tendency to thrombosis and progress of atherosclerosis in apoE-/- LDLR-/- double knockout mouse. Thromb Res. 2005; 116(5):393-401. DOI: 10.1016/j.thromres.2005.01.011. View

20.

Zunker P, Schick A, Padro T, Kienast J, Phillips A, Ringelstein E . Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology. Neurol Res. 1999; 21(8):727-32. DOI: 10.1080/01616412.1999.11741005. View